404 related articles for article (PubMed ID: 34439105)
1. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review.
Rascio F; Spadaccino F; Rocchetti MT; Castellano G; Stallone G; Netti GS; Ranieri E
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439105
[TBL] [Abstract][Full Text] [Related]
2. Mir-20a-5p induced WTX deficiency promotes gastric cancer progressions through regulating PI3K/AKT signaling pathway.
Li J; Ye D; Shen P; Liu X; Zhou P; Zhu G; Xu Y; Fu Y; Li X; Sun J; Xu J; Zhang Q
J Exp Clin Cancer Res; 2020 Oct; 39(1):212. PubMed ID: 33032635
[TBL] [Abstract][Full Text] [Related]
3. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.
Luo Q; Du R; Liu W; Huang G; Dong Z; Li X
Front Oncol; 2022; 12():852383. PubMed ID: 35392233
[TBL] [Abstract][Full Text] [Related]
5. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
Narayanankutty A
Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between miRNA and PI3K/AKT/mTOR signaling pathway in cancer.
Akbarzadeh M; Mihanfar A; Akbarzadeh S; Yousefi B; Majidinia M
Life Sci; 2021 Nov; 285():119984. PubMed ID: 34592229
[TBL] [Abstract][Full Text] [Related]
7. Phytochemicals and Nanoparticles in the Modulation of PI3K/Akt/mTOR Kinases and its Implications in the Development and Progression of Gastrointestinal Cancers: A Review of Preclinical and Clinical Evidence.
Narayanankutty A; Nambiattil S; Mannarakkal S
Recent Pat Anticancer Drug Discov; 2023; 18(3):307-324. PubMed ID: 35670354
[TBL] [Abstract][Full Text] [Related]
8. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Wu CP; Murakami M; Hsiao SH; Chou AW; Li YQ; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2017 Jul; 14(7):2368-2377. PubMed ID: 28597653
[TBL] [Abstract][Full Text] [Related]
10. Recent Updates on the Involvement of PI3K/AKT/mTOR Molecular Cascade in the Pathogenesis of Hyperproliferative Skin Disorders.
Mercurio L; Albanesi C; Madonna S
Front Med (Lausanne); 2021; 8():665647. PubMed ID: 33996865
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol, curcumin, paclitaxel and miRNAs mediated regulation of PI3K/Akt/mTOR pathway: go four better to treat bladder cancer.
Khan K; Quispe C; Javed Z; Iqbal MJ; Sadia H; Raza S; Irshad A; Salehi B; Reiner Ž; Sharifi-Rad J
Cancer Cell Int; 2020 Nov; 20(1):560. PubMed ID: 33292283
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
13. Detailed role of microRNA-mediated regulation of PI3K/AKT axis in human tumors.
Al-Hawary SIS; Ruzibakieva M; Gupta R; Malviya J; Toama MA; Hjazi A; Alkhayyat MRR; Alsaab HO; Hadi A; Alwaily ER
Cell Biochem Funct; 2024 Jan; 42(1):e3904. PubMed ID: 38102946
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.
Ghayad SE; Cohen PA
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):29-57. PubMed ID: 19751211
[TBL] [Abstract][Full Text] [Related]
15. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
17. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer.
Quan Z; Yang Y; Zheng H; Zhan Y; Luo J; Ning Y; Fan S
J Cancer; 2022; 13(13):3434-3443. PubMed ID: 36313041
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
[TBL] [Abstract][Full Text] [Related]
20. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
